The Deadly Cough Syrup Crisis: Child Deaths in
Chhindwara and Rajasthan
In the quiet districts of Madhya
Pradesh and Rajasthan, a heartbreaking health crisis has unfolded, claiming the
lives of at least 11 young children in just two weeks—nine in Madhya
Pradesh's Chhindwara district and two in Rajasthan. What began as
routine seasonal illnesses—colds, fevers, and coughs—spiraled into a nightmare
of kidney failure and sudden deaths. Investigations point to contaminated
cough syrups as the prime suspect.
As of October 3, 2025, inquiries are
ongoing, but the tragedy is a stark reminder of the vulnerabilities in
India’s pharmaceutical supply chain—and the recurring pattern where
government action comes only after fatalities occur.
1. The Tragedy Unfolds
The crisis first emerged in
Chhindwara, where six children under five died of acute kidney failure between
mid-September and early October. By October 1, the toll had risen to nine.
Similar cases surfaced in neighboring Rajasthan, including two more child
deaths linked to suspected cough syrup use.
Victims had consumed syrups such as:
- Coldrif/Coldfref
(Sresan Pharmaceuticals, Tamil Nadu)
- Nextro
(manufacturer unspecified)
- Dextromethorphan hydrobromide syrup (Kaysons Pharma, Jaipur – batches KL-25/147,
KL-25/148)
Symptoms started as viral-like
infections but progressed rapidly to reduced urine output, swelling, and kidney
failure. Parents described how their children initially improved, only to
deteriorate fatally within days.
The echoes of past global scandals
are chilling—such as the 2022 Gambia case, where Indian-made syrups
containing diethylene glycol (DEG) killed over 60 children.
Currently, over 1,400 children
in affected areas are under monitoring, with ASHA workers conducting
door-to-door health checks. No infectious outbreak has been confirmed;
suspicion remains firmly on chemical contamination.
2. Suspected Culprit: DEG-Contaminated Syrups
Investigators believe the syrups may
have been adulterated with diethylene glycol (DEG), a toxic industrial
solvent sometimes substituted for safe pharmaceutical excipients to cut costs.
- Toxic pathway:
DEG poisoning causes gastrointestinal distress, acute kidney injury, and
neurological damage. Children are especially vulnerable, often requiring
urgent dialysis to survive.
- State bans:
Madhya Pradesh has banned dextromethorphan syrups statewide, while
Rajasthan halted 19 suspect batches. Tamil Nadu froze stocks at Sresan
Pharmaceuticals’ plant.
- Testing underway:
The National Centre for Disease Control (NCDC) and CSIR labs
are analyzing samples; results are awaited.
India has faced similar tragedies
before (2023, 2022, earlier decades). A clear pattern of lax quality control
and weak enforcement emerges.
3. Government Response: Quick but Reactive
Authorities have scrambled to
contain the fallout:
- Children with symptoms lasting over two days must now
be observed at civil hospitals.
- Private doctors are barred from independently treating
suspected viral cases.
- Statewide bans imposed on suspect syrups in MP and
Rajasthan.
- Stocks frozen at Sresan Pharma in Tamil Nadu.
Yet critics argue the response is reactive.
India’s regulator, the Central Drugs Standard Control Organisation (CDSCO),
suffers from understaffing and weak post-marketing surveillance. Historically,
bans follow deaths rather than proactive inspections.
4. Accountability: Who Is Responsible?
|
Actor |
Role |
Failures |
Action Taken (Past & Present) |
|
Manufacturers
(Sresan Pharma, Kaysons Pharma) |
Produce/test syrups |
Skipping DEG testing; false certificates |
Stock freezes, temporary suspensions, probes |
|
Suppliers |
Provide excipients |
Supplying industrial-grade materials |
Rarely prosecuted; weak traceability |
|
Regulators (CDSCO/States) |
Approve, inspect, recall |
Weak inspections; delayed recalls |
Investigations, but rarely arrests |
|
Health Depts. |
Distribute via schemes |
No independent testing |
Monitoring protocols introduced |
|
Distributors/Pharmacies |
Sell to consumers |
Ignoring recalls |
Minimal accountability so far |
5. Precautions for Parents
- Avoid self-medication
for children with OTC syrups.
- Check batch numbers
before purchase.
- Buy only from licensed pharmacies.
- If poisoning suspected, rush to hospital immediately
for supportive care (fluids, dialysis).
- Report suspect medicines to drug controllers and
health authorities.
6. Legal Options for Parents
Families seeking justice have
multiple legal remedies:
(a)
Criminal Action
- Bharatiya Nyaya Sanhita (BNS), 2023
- Sec. 106 – Causing death by negligence.
- Sec. 276 & 277 – Adulteration and sale of
adulterated drugs.
- Drugs & Cosmetics Act, 1940
- Sec. 27 – Life imprisonment for spurious/adulterated
drugs.
👉 Parents can file FIRs and complaints with drug
inspectors.
(b)
Consumer Protection
- Compensation claims under the Consumer Protection
Act, 2019 for defective products.
- Commissions at district, state, or national level
depending on claim amount.
- Option for class action complaints.
(c)
Medical Negligence
- Hospitals/pharmacies may be liable if they dispensed
suspect syrups without diligence.
- Remedies via consumer courts or civil suits.
(d)
Writs & PILs
- High Courts (Art. 226) or Supreme Court (Art. 32) for:
- Court-monitored probes (CBI/SIT).
- Interim compensation.
- Reforms in regulatory monitoring.
(e)
Government Liability
If distributed under govt schemes,
the state may be vicariously liable, as courts have held in
vaccine/sterilization mishap cases.
7. Towards Systemic Reform
This tragedy highlights systemic
issues:
- Weak enforcement of Good Manufacturing Practices
(GMPs).
- Lack of routine raw material testing.
- Event-driven regulation instead of preventive
inspections.
- Absence of fast-track compensation frameworks
for victims.
International collaboration with WHO
and stricter CDSCO-led oversight are urgently needed to prevent repeat
disasters.
8. Demands from the Government
To ensure such tragedies are not repeated, urgent systemic reforms are needed. Families, activists, and public health experts demand that the Union and State Governments:
-
Mandatory DEG and PEG Testing
-
Require batch-wise testing of all syrups for toxic solvents like diethylene glycol (DEG) and ethylene glycol (EG) before market release.
-
-
Strengthen CDSCO and State Drug Regulators
-
Increase staffing, training, and funding for the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers.
-
Conduct risk-based inspections of pharma plants, not just paper audits.
-
-
Transparent Drug Recalls
-
Establish a public online database of banned/withdrawn batches accessible to parents, doctors, and pharmacists in real time.
-
-
Fast-Track Compensation Mechanism
-
Create a no-fault compensation fund for victims of contaminated drugs, ensuring families don’t spend years in courts.
-
-
Accountability for Manufacturers
-
Strictly enforce BNS 2023 and Drugs & Cosmetics Act provisions against negligent manufacturers, including criminal prosecutions and permanent license cancellations.
-
-
Independent Forensic Testing Labs
-
Expand government-run and NABL-accredited labs to ensure unbiased, rapid testing of drugs across all states.
-
-
Public Awareness Campaigns
-
Launch nationwide campaigns urging parents to avoid self-medicating children, verify medicines, and report adverse reactions.
-
-
Whistleblower Protection
-
Introduce legal protections for insiders in pharma companies who expose unsafe practices.
-
9. Conclusion
The Chhindwara cough syrup crisis is
not just a local tragedy but a national alarm bell. Parents
mourning their children must navigate complex legal paths for justice—from
criminal prosecutions under the BNS to consumer claims, negligence
suits, and constitutional remedies.
But beyond courtroom battles, the
real solution lies in systemic reform—ensuring that profit never
trumps child safety. Until then, each tragedy will only add to India’s grim
list of preventable deaths. Children’s lives are too precious to be the price
of regulatory failure.
#CoughSyrupCrisis #DrugSafety #PublicHealthCrisis #JusticeForChildren #PharmaAccountability
.jpeg)
.jpeg)


